Heidegger Isabel-Maria,

University / Clinic: FK-Building
Institute: Department of Urology
 
Research Area:

Email: isabel-maria.heidegger@i-med.ac.at
Web: urolab.uki.at/page.cfm?vpath=index


Research Topic:


Selected publications:
 
  Pichler R, Fritz J, Heidegger I, Steiner E, Culig Z, Klocker H, Fuchs D
The predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer.
Cancer Sci. 2017 Jan 20. doi: 10.1111/cas.13171. [Epub ahead of print]

  Höfer J, Akbor M, Handle F, Ofer P, Puhr M, Parson W, Culig Z, Klocker H, Heidegger I
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Oncotarget. 2016 Sep 13;7(37):59781-59794. doi: 10.18632/oncotarget.10926.

  Heidegger I, Höfer J, Luger M, Pichler R, Klocker H, Horninger W, Steiner E, Jochberger S, Culig Z
Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?
Prostate. 2015 Dec;75(16):1904-9. doi: 10.1002/pros.23086. Epub 2015 Aug 26.

  Pichler R, Borena W, Schäfer G, Manzl C, Culig Z, List S, Neururer S, Von Laer D, Heidegger I, Klocker H, Horninger W, Steiner H, Brunner A
Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot.
World J Urol. 2015 Dec;33(12):2145-51. doi: 10.1007/s00345-015-1539-y. Epub 2015 Mar 19.

  Ofer P, Heidegger I, Eder I, Schöpf B, Neuwirt H, Geley S, Klocker H, Massoner P
Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.
Mol Endocrinol. 2015 Dec;29(12):1694-707. doi: 10.1210/me.2015-1073. Epub 2015 Oct 9.

  Heidegger I, Kern J, Ofer P, Klocker H, Massoner P
Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis.
Oncotarget. 2014 May 15;5(9):2723-35.

  Heidegger I, Klocker H, Steiner E, Skradski V, Ladurner M, Pichler R, Schäfer G, Horninger W, Bektic J
[-2]proPSA is an early marker for prostate cancer aggressiveness.
Prostate Cancer Prostatic Dis. 2014 Mar;17(1):70-4.

  Puhr M, Höfer J, Neuwirt H, Eder I, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.
Oncotarget. 2014 Dec 15;5(23):12043-56.

  Heidegger I, Massoner P, Eder I, Pircher A, Pichler R, Aigner F, Bektic J, Horninger W, Klocker H
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.
J Steroid Biochem Mol Biol. 2013 Jun 20;138C:248-256.

  Heidegger I, Pichler R, Müller B, Klocker H, Oswald D, Haid B, Zelger B, Horninger W, Oswald J
Is real-time PCR the correct method to evaluate the incidence of human papillomavirus in prepuces of asymptomatic boys and men?
World J Urol. 2013 Oct 22.

  Puhr M, Höfer J, Schäfer G, Erb H, Oh S, Klocker H, Heidegger I, Neuwirt H, Culig Z
Epithelial to Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and is Mediated by Reduced Expression of miR-200c and miR-205.
Am J Pathol. 2012 Oct 3. pii: S0002-9440(12)00653-0. doi: 10.1016/j.ajpath.2012.08.011

  Heidegger I, Ofer P, Doppler W, Rotter V, Klocker H, Massoner P
Diverse functions of IGF/insulin signaling in malignant and non-cancerous prostate cells: proliferation in cancer cells and differentiation in non-cancerous cells.
Endocrinology. 2012 Oct;153(10):4633-43

  Heidegger I, Ladurner M, Skradski V, Klocker H, Schäfer G, Horninger W, Bektic J
Adverse pathological findings in needle biopsy gleason score 6 prostate cancers with low and intermediate preoperative PSA levels following radical prostatectomy.
Anticancer Res. 2012 Dec;32(12):5481-5.

  Heidegger I, Pircher A, Klocker H, Massoner P
Targeting the insulin-like growth factor network in cancer therapy.
Cancer Biol Ther. 2011 Apr 15;11(8):701-7

  Massoner P, Ladurner Rennau M, Heidegger I, Kloss-Brandstätter A, Summerer M, Reichhart E, Schäfer G, Klocker H
Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-beta treatment.
Am J Pathol. 179:2905-19, 2011.